BR112021025956A2 - Anticorpo dirigido contra o fragmento amino-terminal da apoe de 12 kda - Google Patents
Anticorpo dirigido contra o fragmento amino-terminal da apoe de 12 kdaInfo
- Publication number
- BR112021025956A2 BR112021025956A2 BR112021025956A BR112021025956A BR112021025956A2 BR 112021025956 A2 BR112021025956 A2 BR 112021025956A2 BR 112021025956 A BR112021025956 A BR 112021025956A BR 112021025956 A BR112021025956 A BR 112021025956A BR 112021025956 A2 BR112021025956 A2 BR 112021025956A2
- Authority
- BR
- Brazil
- Prior art keywords
- terminal fragment
- apoe
- kda
- amino
- directed against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183405.0A EP3757125A1 (en) | 2019-06-28 | 2019-06-28 | Antibody directed against the apoe amino-terminal fragment of 12 kda |
| PCT/EP2020/067890 WO2020260491A2 (en) | 2019-06-28 | 2020-06-25 | New antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025956A2 true BR112021025956A2 (pt) | 2022-02-08 |
Family
ID=67225987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025956A BR112021025956A2 (pt) | 2019-06-28 | 2020-06-25 | Anticorpo dirigido contra o fragmento amino-terminal da apoe de 12 kda |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220242939A1 (https=) |
| EP (2) | EP3757125A1 (https=) |
| JP (1) | JP2022537736A (https=) |
| KR (1) | KR20220029653A (https=) |
| CN (1) | CN114008074A (https=) |
| AU (1) | AU2020304855A1 (https=) |
| BR (1) | BR112021025956A2 (https=) |
| CA (1) | CA3140999A1 (https=) |
| IL (1) | IL289271A (https=) |
| MX (1) | MX2021016160A (https=) |
| WO (1) | WO2020260491A2 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168045A (en) * | 1989-08-18 | 1992-12-01 | The Scripps Research Institute | Diagnostic systems and methods using polypeptide analogs of apolipoprotein e |
| NZ581835A (en) * | 2007-06-12 | 2012-09-28 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
| JP2009092550A (ja) * | 2007-10-10 | 2009-04-30 | Japan Health Science Foundation | うつ病またはうつ状態の同定方法 |
| CN102459335B (zh) * | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| WO2011084714A2 (en) * | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| US20170218058A1 (en) * | 2016-01-28 | 2017-08-03 | Alector, LLC | Anti-apoe4 antigen-binding proteins and methods of use thereof |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018137705A1 (en) * | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
-
2019
- 2019-06-28 EP EP19183405.0A patent/EP3757125A1/en not_active Withdrawn
-
2020
- 2020-06-25 KR KR1020227000512A patent/KR20220029653A/ko active Pending
- 2020-06-25 MX MX2021016160A patent/MX2021016160A/es unknown
- 2020-06-25 WO PCT/EP2020/067890 patent/WO2020260491A2/en not_active Ceased
- 2020-06-25 AU AU2020304855A patent/AU2020304855A1/en not_active Abandoned
- 2020-06-25 CN CN202080045874.2A patent/CN114008074A/zh active Pending
- 2020-06-25 CA CA3140999A patent/CA3140999A1/en active Pending
- 2020-06-25 JP JP2021575056A patent/JP2022537736A/ja active Pending
- 2020-06-25 BR BR112021025956A patent/BR112021025956A2/pt unknown
- 2020-06-25 EP EP20734930.9A patent/EP3990486A2/en active Pending
- 2020-06-25 US US17/617,469 patent/US20220242939A1/en not_active Abandoned
-
2021
- 2021-12-22 IL IL289271A patent/IL289271A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020304855A1 (en) | 2021-12-23 |
| EP3757125A1 (en) | 2020-12-30 |
| IL289271A (en) | 2022-02-01 |
| US20220242939A1 (en) | 2022-08-04 |
| CN114008074A (zh) | 2022-02-01 |
| JP2022537736A (ja) | 2022-08-29 |
| CA3140999A1 (en) | 2020-12-30 |
| MX2021016160A (es) | 2022-04-06 |
| EP3990486A2 (en) | 2022-05-04 |
| KR20220029653A (ko) | 2022-03-08 |
| WO2020260491A2 (en) | 2020-12-30 |
| WO2020260491A3 (en) | 2021-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190983A1 (ru) | Новое антитело к с-kit | |
| BR112021019107A2 (pt) | Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| BR112022003147A2 (pt) | Novos anticorpos anti-cldn18.2 | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| BR112012014975A2 (pt) | novos anticorpos antagonistas e seus fragmentos fab contra gpvi e seus usos | |
| AR110114A1 (es) | ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
| JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
| JOP20230311A1 (ar) | أجسام مضادة لـ sirp-ألفا | |
| BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
| CR20210324A (es) | Anticuerpos anti-pmel 17 y conjugados de los mismos | |
| MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. | |
| BR112018000909A2 (pt) | imunoconjugados de il22 | |
| BR112023017556A2 (pt) | Anticorpo contra nkp46 e aplicação do mesmo | |
| ZA202110285B (en) | Antibodies and methods of use | |
| MX2023002850A (es) | Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap). | |
| BR112021025956A2 (pt) | Anticorpo dirigido contra o fragmento amino-terminal da apoe de 12 kda | |
| MX2025007017A (es) | Anticuerpo que se une a piroglutamato de beta amiloide que inicia en la posicion 3 (abetape3) | |
| WO2025081117A3 (en) | Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates | |
| MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
| MX2023008029A (es) | Proteinas de fusion de anticuerpo y sialidasa-pd-1 y metodos para utilizarlas. | |
| JOP20210339A1 (ar) | أجسام مضادة لـ angpt2 |